Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by bigmack1on Jun 04, 2021 4:44am
729 Views
Post# 33328060

Must be big

Must be big

I woke up with clarity and hunger for more shares today. Amalgamation indicates to me that they are preparing for a larger transaction. The sp is far too stagnant and unmovable. I believe this is the second large clue. My bet is that they are currently wrapping up negotiations with BP.  Otherwise, we would have more attention from upper management. They would be actively trying to move the current sp north of $4 with nr's etc. I believe that this is going to be halted at any moment. It's simply too quiet given the circumstances. I believe that much much more is going on behind closed doors. It's far too quiet to be normal!

This is not investment advice. If I had investment advice, it would probably be to get out of high risk pharma stock :)

But I am personally certain that something BIG is going on. 


IMO

DYODD

 

<< Previous
Bullboard Posts
Next >>